A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA “grey zone”.
MDNA Life Sciences announces that it has entered into an exclusive license agreement with its first international commercial partner.
MDNA Life Sciences has entered into a collaboration agreement with the University of Oxford to further the development and validation of MDNA’s non-invasive blood-based test for endometriosis.
A clinical study published in the American Health & Drug Benefits journal describes the Mitomic Prostate Core Test’s impact on patient management and the biopsy decision-making process.
The diagnostics game has changed dramatically over the past 15 years. Old-school companies placed their bets on high-volume, low-margin tests, but today’s molecular diagnostics players are all about value proposition. The market is hungry for simple tests that impact patient outcomes while also taking costs out of the system.